Microcalcifications play a crucial role in breast cancer screening, representing a potential biomarker of early-stage cancer in around 20% of cases confirmed by pathological analysis.

Today, in clinical practice, radiologists refer to the ACR-BIRADS classification “Chapter Microcalcifications” to establish a diagnosis whose positive predictive value for cancer varies from 2% to a maximum of 95%. This significant inaccuracy leads to perform marcrobiopsies for ACR 4 and 5 categories, whose turn out to be benign in 80% of cases after anatomopathological analysis.

The macrobiopsy procedure is deleterious for the patient (anxiety, problem of borderline lesions), time-consuming for the physician, and costly for the healthcare system. The challenge therefore lies in identifying cases that are likely to evolve into cancer, to enable agile, early and personalized treatment, and thus avoid unnecessary macrobiopsies for millions of patients.

XIMED aims to solve the overuse of macrobiopsies by exploiting a PATENTED X-Ray PHASE CONTRAST imaging technology that enables, for the first time, the creation of a NEW SEMIOLOGY of breast microcalcifications.

Through our product PhoeniX, we aim to revolutionize clinical workflow for early detection of breast cancer by accurately qualifying microcalcifications directly on mammographic images, thus avoiding unnecessary macrobiopsies for millions of women.